ストックスクリーナーアプリを入手
6.07
3.19%
-0.20
アフターアワーズ：
5.92
-0.15
-2.47%
前日終値:
$6.27
開ける：
$6.26
24時間の取引高:
38,577
Relative Volume:
0.50
時価総額：
$101.52M
収益：
-
当期純損益:
$-14.88M
株価収益率:
-6.1939
EPS:
-0.98
ネットキャッシュフロー:
$-10.29M
1週間 パフォーマンス:
-0.50%
1か月 パフォーマンス:
-3.80%
6か月 パフォーマンス:
+23.12%
1年 パフォーマンス:
-12.54%
1日の値動き範囲:
$5.99
$6.4399
1週間の範囲:
$5.99
$6.70
52週間の値動き範囲:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.07 | 104.87M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-09 | 開始されました | Lake Street | Buy |
| 2024-12-04 | 開始されました | D. Boral Capital | Buy |
Coya Therapeutics Inc (COYA) 最新ニュース
Is Coya Therapeutics Inc. stock poised for growthTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is now a turning point for Coya Therapeutics Inc.Portfolio Return Summary & Precise Buy Zone Tips - newser.com
What data driven models say about Coya Therapeutics Inc.’s futureBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Candlestick signals on Coya Therapeutics Inc. stock todayQuarterly Profit Review & Safe Entry Trade Reports - newser.com
Should you hold or exit Coya Therapeutics Inc. nowTrade Volume Summary & Fast Entry High Yield Tips - newser.com
Quantitative breakdown of Coya Therapeutics Inc. recent move2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
News impact scoring models applied to Coya Therapeutics Inc.2025 Key Highlights & Precise Buy Zone Tips - newser.com
What momentum shifts mean for Coya Therapeutics Inc.Quarterly Investment Review & Low Volatility Stock Suggestions - newser.com
Coya Therapeutics (NASDAQ:COYA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-09 03:57:14 - newser.com
Ranking Coya Therapeutics Inc. among high performing stocks via tools2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - BioSpace
What analysts say about Coya Therapeutics Inc stockPrice Momentum Alerts & Budget Friendly Portfolio Growth - earlytimes.in
Predicting Coya Therapeutics Inc. trend using moving averages2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
What sentiment indicators say about Coya Therapeutics Inc. stockWeekly Risk Report & Community Consensus Picks - newser.com
How to integrate Coya Therapeutics Inc. into portfolio analysis toolsWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Will Coya Therapeutics Inc. stock outperform value stocksPrice Action & Risk Controlled Daily Trade Plans - newser.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.20 Consensus PT from Analysts - Defense World
What drives Coya Therapeutics Inc stock priceDividend Yield Trends & Trusted Financial Advisors at No Cost - earlytimes.in
BTIG Reiterates Buy Rating on COYA with $15 Price Target | COYA Stock News - GuruFocus
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from BTIG Research - MarketBeat
Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support - TipRanks
Coya completes FTD combination therapy trial enrolment - Yahoo Finance
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - Quantisnow
COYA Stock Analyst Rating: D. Boral Capital Maintains "Buy" Rati - GuruFocus
Coya Therapeutics' (COYA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Coya Therapeutics announces completion of patient enrollment - MarketScreener
Coya Therapeutics, Inc. Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - MarketScreener
Coya Therapeutics (NASDAQ:COYA) Trading Up 3.4%Should You Buy? - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Trading Up 3.4% – Should You Buy? - Defense World
Is Coya Therapeutics Inc. forming a bottoming base2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
New trial to test effectiveness of COYA 302 to slow ALS progression - ALS News Today
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
Coya Therapeutics Inc (COYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SNYDER DAVID S | Chief Financial Officer |
Nov 14 '24 |
Buy |
7.19 |
1,800 |
12,934 |
8,800 |
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
5.74%
大文字化:
|
ボリューム (24 時間):